Products Clinical Development Strategy Cancer patients face life-threatening problems from primary cancer  which tends to grow locally where it originated, such as seen in brain cancer, and from distant tumor metastases to vital organs (including to the lung, liver and brain) such as seen in malignant melanoma. Many of these patients have no approved therapeutic options remaining, and we believe they desire to be in clinical trials with experimental drugs that do not have proven safety or efficacy because they hope the trial may provide a better outcome than no treatment.   Product Candidates To address both of these clinical conditions, we are developing two different investigational gene transfer products that could be used in either condition. We believe that in certain cancer settings these two treatments could possibly be used together.   We are initially developing our Prodrug Activator product candidate, Toca 511, for treating GBM, and have initiated our Phase 1/2 human clinical study.     Our Immunotherapeutic product candidate, Toca 621, is anticipated to be evaluated initially for treating Malignant Melanoma.  Toca 621 is currently in pre-clinical evaluation.    We believe these initial cancer types should allow for rapid demonstration of proof of concept in humans for our gene transfer drug candidates under development.     Product Candidates  Prodrug Activator: Toca 511  Immunotherapeutic: Toca 621   Programs  Brain Cancer (GBM)  Malignant Melanoma   Also see: Breakthrough Technology                                            Dictionary     Dictionary of Cancer Terms             Privacy Policy | Terms of Use | www.tocagen.com   3030 Bunker Hill St. Suite 230  San Diego, CA 92109          Main (858) 412-8400  Fax (858) 412-8499  © Copyright 2010 Tocagen Inc.